Delphine Borchiellini
Université Côte d'Azur(FR)Centre Antoine Lacassagne(FR)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, Renal and related cancers, Cancer Genomics and Diagnostics
Most-Cited Works
- → Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma(2019)3,317 cited
- → Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial(2020)728 cited
- → Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer(2023)299 cited
- → Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer(2023)162 cited
- → Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study(2019)159 cited
- → Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial(2022)128 cited
- → Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study(2023)123 cited
- → Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.(2019)120 cited
- → Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas(2017)112 cited
- → Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.(2021)108 cited